vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与CANTALOUPE, INC.（CTLP）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是CANTALOUPE, INC.的1.9倍（$152.6M vs $78.7M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -0.1%，领先34.6%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs 6.8%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $-614.0K），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 7.7%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
CPRX vs CTLP — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $78.7M |
| 净利润 | $52.7M | $-70.0K |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | 2.0% |
| 净利率 | 34.5% | -0.1% |
| 营收同比 | 7.6% | 6.8% |
| 净利润同比 | -5.8% | -101.4% |
| 每股收益（稀释后） | $0.40 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $78.7M | ||
| Q3 25 | $148.4M | $80.9M | ||
| Q2 25 | $146.6M | $82.6M | ||
| Q1 25 | $141.4M | $75.4M | ||
| Q4 24 | $141.8M | $73.7M | ||
| Q3 24 | $128.7M | $70.8M | ||
| Q2 24 | $122.7M | $72.7M | ||
| Q1 24 | $98.5M | $67.9M |
| Q4 25 | $52.7M | $-70.0K | ||
| Q3 25 | $52.8M | $-919.0K | ||
| Q2 25 | $52.1M | $6.8M | ||
| Q1 25 | $56.7M | $49.2M | ||
| Q4 24 | $55.9M | $5.0M | ||
| Q3 24 | $43.9M | $3.6M | ||
| Q2 24 | $40.8M | $2.2M | ||
| Q1 24 | $23.3M | $4.7M |
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | 39.6% |
| Q4 25 | 40.5% | 2.0% | ||
| Q3 25 | 44.7% | 2.0% | ||
| Q2 25 | 45.2% | 6.3% | ||
| Q1 25 | 44.8% | 9.1% | ||
| Q4 24 | 44.3% | 8.4% | ||
| Q3 24 | 39.6% | 5.8% | ||
| Q2 24 | 44.2% | 4.9% | ||
| Q1 24 | 27.5% | 6.3% |
| Q4 25 | 34.5% | -0.1% | ||
| Q3 25 | 35.6% | -1.1% | ||
| Q2 25 | 35.6% | 8.3% | ||
| Q1 25 | 40.1% | 65.2% | ||
| Q4 24 | 39.4% | 6.7% | ||
| Q3 24 | 34.1% | 5.0% | ||
| Q2 24 | 33.2% | 3.0% | ||
| Q1 24 | 23.6% | 6.9% |
| Q4 25 | $0.40 | $0.00 | ||
| Q3 25 | $0.42 | $-0.02 | ||
| Q2 25 | $0.41 | $0.10 | ||
| Q1 25 | $0.45 | $0.65 | ||
| Q4 24 | $0.44 | $0.07 | ||
| Q3 24 | $0.35 | $0.04 | ||
| Q2 24 | $0.33 | $0.03 | ||
| Q1 24 | $0.19 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $53.0M |
| 总债务越低越好 | — | $37.7M |
| 股东权益账面价值 | $954.3M | $252.5M |
| 总资产 | $1.1B | $381.9M |
| 负债/权益比越低杠杆越低 | — | 0.15× |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $53.0M | ||
| Q3 25 | $689.9M | $55.0M | ||
| Q2 25 | $652.8M | $51.1M | ||
| Q1 25 | $580.7M | $46.3M | ||
| Q4 24 | $517.6M | $27.7M | ||
| Q3 24 | $442.3M | $33.1M | ||
| Q2 24 | $375.7M | $58.9M | ||
| Q1 24 | $310.4M | $50.2M |
| Q4 25 | — | $37.7M | ||
| Q3 25 | — | $38.3M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | — | $37.3M | ||
| Q2 24 | — | $37.5M | ||
| Q1 24 | — | $38.1M |
| Q4 25 | $954.3M | $252.5M | ||
| Q3 25 | $920.2M | $251.8M | ||
| Q2 25 | $856.0M | $251.0M | ||
| Q1 25 | $794.3M | $240.7M | ||
| Q4 24 | $727.6M | $190.1M | ||
| Q3 24 | $660.9M | $186.2M | ||
| Q2 24 | $608.7M | $181.7M | ||
| Q1 24 | $561.4M | $178.8M |
| Q4 25 | $1.1B | $381.9M | ||
| Q3 25 | $1.1B | $389.5M | ||
| Q2 25 | $971.9M | $381.9M | ||
| Q1 25 | $908.9M | $370.5M | ||
| Q4 24 | $851.4M | $303.0M | ||
| Q3 24 | $772.0M | $312.1M | ||
| Q2 24 | $706.4M | $335.6M | ||
| Q1 24 | $646.7M | $319.9M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $3.1M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $-614.0K |
| 自由现金流率自由现金流/营收 | 29.4% | -0.8% |
| 资本支出强度资本支出/营收 | 0.0% | 4.8% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $25.8M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $3.1M | ||
| Q3 25 | $32.4M | $7.0M | ||
| Q2 25 | $71.3M | $9.4M | ||
| Q1 25 | $60.0M | $22.4M | ||
| Q4 24 | $70.9M | $522.0K | ||
| Q3 24 | $72.9M | $-12.0M | ||
| Q2 24 | $64.1M | $14.3M | ||
| Q1 24 | $31.9M | $14.7M |
| Q4 25 | $44.9M | $-614.0K | ||
| Q3 25 | — | $3.5M | ||
| Q2 25 | $71.3M | $4.3M | ||
| Q1 25 | — | $18.6M | ||
| Q4 24 | $70.8M | $-3.8M | ||
| Q3 24 | $72.6M | $-15.8M | ||
| Q2 24 | $64.1M | $8.5M | ||
| Q1 24 | $31.7M | $11.4M |
| Q4 25 | 29.4% | -0.8% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | 48.6% | 5.3% | ||
| Q1 25 | — | 24.6% | ||
| Q4 24 | 49.9% | -5.1% | ||
| Q3 24 | 56.4% | -22.3% | ||
| Q2 24 | 52.3% | 11.7% | ||
| Q1 24 | 32.2% | 16.9% |
| Q4 25 | 0.0% | 4.8% | ||
| Q3 25 | 0.0% | 4.2% | ||
| Q2 25 | 0.0% | 6.2% | ||
| Q1 25 | 0.0% | 5.1% | ||
| Q4 24 | 0.1% | 5.8% | ||
| Q3 24 | 0.2% | 5.4% | ||
| Q2 24 | 0.0% | 7.9% | ||
| Q1 24 | 0.2% | 4.8% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | 1.38× | ||
| Q1 25 | 1.06× | 0.46× | ||
| Q4 24 | 1.27× | 0.10× | ||
| Q3 24 | 1.66× | -3.36× | ||
| Q2 24 | 1.57× | 6.47× | ||
| Q1 24 | 1.37× | 3.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
